Elan Corporation PLC
Investors:
Emer Reynolds, 353-1-709-4000
800-252-3526
or
Media:
Anita Kawatra, 212-407-5755
800-252-3526

Elan Corporation, plc (NYSE: ELN) ("Elan") today confirmed that it is
in negotiations with a third party for the disposition of certain of
Elan's European operations, primarily consisting of its sales and
marketing business there. Elan cannot make any assurances that the
transaction will be completed or the timing of such completion.

About Elan

Elan is focused on the discovery, development, manufacturing, sale and marketing
of novel therapeutic products in neurology, severe pain and autoimmune diseases.
Elan shares trade on the New York, London and Dublin Stock Exchanges.

This document contains forward-looking statements about the potential sale of
certain of Elan's European operations that involve substantial risks and
uncertainties. You can identify these statements by the fact that they use words
such as "anticipate", "estimate", "project", "envisage", "intend", "plan",
"believe" and other words and terms of similar meaning in connection with any
discussion of future events. Among the factors that could cause actual results
to differ materially from those described herein are the following: the outcome
of Elan's negotiations, including the execution of definitive documentation,
with respect to the disposition of such European operations; and the
satisfaction of any conditions to the completion of such disposition on a timely
basis or at all. A further list and description of these risks, uncertainties
and other matters can be found in Elan's Annual Report on Form 20-F for the
fiscal year ended December 31, 2002, and in its Reports of Foreign Issuer on
Form 6-K. Elan assumes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.

    KEYWORD: IRELAND INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL
    PHARMACEUTICAL MEDICAL DEVICES SOURCE: Elan Corporation, plc